NEW CUSTOM ALGORITHM FOR COPY NUMBER DETECTION IN MYELOID MALIGNANCIES USING A TARGETED NGS PANEL

EHA Library, Beñat Ariceta, 325165

THE MOLECULAR BASIS AND CLINICAL OUTCOMES OF CALM-MLLT10 FUSION POSITIVE ACUTE LEUKEMIA

EHA Library, Tong Wang, 325168

PRL-PRLR AXIS IMPLICATION IN CHEMORESISTANCE AND PROLIFERATION IN ACUTE MYELOID LEUKEMIA

EHA Library, Laia Cuesta-Casanovas, 325169

MAIT CELLS NUMBERS AND FREQUENCIES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AT DIAGNOSIS: ASSOCIATION WITH CYTOGENETIC PROFILE AND GENE MUTATIONS.

EHA Library, Thibault Comont, 325170

CHECKPOINT KINASE 1 IS OVEREXPRESSED, BY POST-TRANSCRIPTIONAL REGULATION, IN IMMATURE AND MONOBLASTIC / MONOCYTIC ACUTE MYELOID LEUKEMIA

EHA Library, Leonor M. Sarmento, 325172

METABOLIC PECULIARITY OF PML/RARA EXPRESSING CELLS AND ARSENIC TRIOXIDE RESISTANCE

EHA Library, Nelida I. Noguera, 325174

ZINC IN THE MODULATION OF THE DNA DAMAGE RESPONSE – PREVENTIVE, GENOTOXIC AND CYTOTOXIC ROLES IN ACUTE MYELOID LEUKEMIA

EHA Library, Ana Ribeiro, 325175

LINKING CDK6 TO THE EPIGENOME

EHA Library, Karoline Kollmann, 325176

MELFLUFEN DEMONSTRATES HIGH EFFICACY IN CYTARABINE AND VENETOCLAX RESISTANT AML MODELS

EHA Library, Ana Slipicevic, 325178

ASSOCIATION OF ATG10 FUNCTIONAL GENETIC VARIANTS IN ACUTE MYELOID LEUKEMIA

EHA Library, Anabela Areias, 325179

QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS HIGHLY ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Musa Yilmaz, 325184

VALIDATION AND CLINICAL APPLICATION OF AN UNSUPERVISED ANALYSIS APPROACH TO MEASURABLE RESIDUAL DISEASE TESTING IN ACUTE MYELOID LEUKEMIA

EHA Library, Nicholas McCarthy, 325186

COMPARATIVE BIOAVAILABILITY OF A NOVEL ORAL FORMULATION OF ARSENIC TRIOXIDE IN PATIENTS UNDERGOING CONSOLIDATION THERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA: FINAL ANALYSIS OF THE ALLG APML5 TRIAL

EHA Library, Harry J Iland, 325187

CLINICAL IMPACT OF SENSITIVE DNMT3A, TET2, OR ASXL1 MUTATION DETECTION IN ACUTE MYELOID LEUKEMIA PATIENTS PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Madlen Jentzsch, 325189

PREVALENCE AND PROGNOSTIC IMPACT OF IDH MUTATIONS IN THE REAL-WORLD SETTING: RESULTS FROM THE PROSPECTIVE IDH SCREENING COHORT OF THE SAL AML REGISTRY

EHA Library, Christoph Röllig, 325190

PROGNOSTIC IMPACT OF CONVENTIONAL CYTOGENETICS IN ACUTE MYELOID LEUKEMIA (AML) TREATED WITH DECITABINE AND VENETOCLAX (DEC10-VEN)

EHA Library, Sangeetha Venugopal, 325194

PRELIMINARY RESULTS OF V-FAST, A PHASE 1B MASTER TRIAL TO INVESTIGATE CPX-351 COMBINED WITH TARGETED AGENTS IN NEWLY DIAGNOSED AML

EHA Library, Vinod A. Pullarkat, 325196

PHASE 1 FIRST-IN-HUMAN STUDY OF IRREVERSIBLE FLT3 INHIBITOR FF-10101-01 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Mark Levis, 325197

HEMATOLOGIC ADVERSE EVENTS AND MANAGEMENT STRATEGIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN FIRST REMISSION RECEIVING ORAL AZACITIDINE (ORAL-AZA) IN THE PHASE 3 QUAZAR AML-001 TRIAL

EHA Library, Farhad Ravandi-Kashani, 325199

MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VERSUS INTENSIVE CHEMOTHERAPY IN FLT3 MUTATED ACUTE MYELOID LEUKEMIA. A RWE STUDY

EHA Library, Adolfo De La Fuente, 325201

CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH GILTERITINIB WHO RECEIVED PRIOR MIDOSTAURIN OR SORAFENIB

EHA Library, Zheng Ge, 325208

CLONAL HEMATOPOIESIS IN PERIPHERAL STEM CELLS AT LEUKAPHERESIS AS PREDICTIVE FACTOR FOR THERAPY-RELATED MYELOID NEOPLASMS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION

EHA Library, Doriana Gramegna, 325209

ALICE MAINTAINS HIGH CLINICAL RESPONSE RATES SUPPORTING THE EFFICACY OF IADADEMSTAT COMBINATION WITH AZACITIDINE IN AML MANAGEMENT

EHA Library, Olga Salamero, 325210

A PHASE 1A/B DOSE ESCALATION STUDY OF THE MYC REPRESSOR APTO-253 IN PATIENTS WITH RELAPSED OR REFRACTORY AML OR HIGH-RISK MDS

EHA Library, Rafael Bejar, 325212

SYNERGISTIC EFFECT OF AZACITIDINE AND HOMOHARRINGTONINE IN ACUTE MYELOID LEUKEMIA WITH GATA2 MUTATION

EHA Library, Zheng Ge, 325213

MONITORING OF POST-TRANSPLANT MLL-PTD AS MINIMAL RESIDUAL DISEASE CAN PREDICT RELAPSE AFTER ALLOGENEIC HSCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME

EHA Library, Mengge Gao, 325214

AZACITIDINE IN COMPARISON TO INTENSIVE CHEMOTHERAPY AND BEST SUPPORTIVE CARE IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, A DATAML REGISTRY STUDY

EHA Library, Noémie Gadaud, 325216

PROGNOSTIC IMPACT OF MINIMAL REDISUAL DISEASE ASSESSMENT IN ELDERLY PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA. A COMPARISON BETWEEN CPX-351 AND INTENSIFIED FLUDARABINE-BASED REGIMENS

EHA Library, Fabio Guolo, 325219

ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION WAS SUPERIOR TO CONSOLIDATION CHEMOTHERAPY IN HIGH-RISK CN-AML WITH BIALLELIC CEBPA MUTATIONS BASED ON A MUTI-GENE PANEL AND NOMOGRAM MODEL

EHA Library, Li-Xin Wu, 325220

N-TERMINAL FRAGMENT OF BRAIN NATRIURETIC PEPTIDE (PBNP) IS A NOVEL INDEPENDENT PROGNOSTIC MARKER FOR SURVIVAL AND RESPONSE TO INTENSIVE CHEMOTHERAPY IN AML

EHA Library, Irene Graf, 325221

EFFICACY AND SAFETY OF ASPACYTARABINE (BST-236) AS A FIRST-LINE MONOTHERAPY FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA UNFIT FOR STANDARD CHEMOTHERAPY

EHA Library, Jessica K. Altman, 325222

TRIPLE COMBINATION OF HMA, VENETOCLAX, AND FLT3 INHIBITOR PRODUCES HIGHER FLT3 PCR CLEARANCE, FLOW MRD NEGATIVITY, AND IMPROVED MEDIAN OS COMPARED WITH DOUBLETS OF HMA WITH FLT3 INHIBITOR

EHA Library, Musa Yilmaz, 325224

PROGNOSTIC VALUE OF CRH IN ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX AND DECITABINE

EHA Library, Maria Siddiqui, 325226

ACTIVITY OF DECITABINE COMBINED WITH ALL-TRANS RETINOIC ACID IN OLIGOBLASTIC AML: RESULTS FROM A RANDOMIZED 2X2 PHASE II TRIAL

EHA Library, Christoph Rummelt, 325227

EFFICACY AND SAFETY OF ENASIDENIB AND AZACITIDINE COMBINATION IN PATIENTS WITH IDH2 MUTATED ACUTE MYELOID LEUKEMIA AND NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

EHA Library, Sangeetha Venugopal, 325231

REAL-LIFE PRELIMINARY EXPERIENCE OF TREATMENT OF NEWLY-DIAGNOSED AND REFRACTORY/RELAPSED (R/R) ACUTE MYELOID LEUKEMIA PATIENTS WITH COMBINATION OF VENETOCLAX WITH HYPOMETHYLATING AGENTS

EHA Library, Carlos Jimenez-Vicente, 325232

BCL-2 EXPRESSION IN ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS AND IMPACT ON OUTCOMES ACCORDING TO DIFFERENT THERAPEUTIC STRATEGIES

EHA Library, Mario Tiribelli, 325237

INTERMEDIATE OR STANDARD DOSE CYTARABINE AS POST REMISSION THERAPY IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA: IMPACTS ON OUTCOMES AND HEALTH CARE RESOURCE CONSUMPTION

EHA Library, Jean Galtier, 325242

APPLICATION OF MACHINE LEARNING IN STRATIFYING MINIMAL RESIDUAL DISEASE LEVEL WITH FLOW CYTOMETRY IN ACUTE MYELOID LEUKEMIA

EHA Library, Bor-Sheng Ko, 325243

INDUCTION CHEMOTHERAPY WITH CYTARABINE, DAUNORRUBICIN AND ETOPOSIDE VERSUS STANDARD-DOSE CYTARABINE AND DAUNORRUBICIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Catia Reis, 325248

NEXT STEP AFTER COMPLETE REMISSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Claudia Núñez-Torron Stock, 325249

ROLE OF EXTRACELLULAR VESICLE-INDUCED MYELOID-DERIVED SUPPRESSOR CELLS IN ACUTE MYELOID LEUKEMIA

EHA Library, Haizhou Xing, 325250

DELAY IN THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA, COMPARISON BEFORE AND AFTER SARS-COV-2: A SINGLE CENTRE STUDY

EHA Library, Cristina Alburquerque-Prieto, 325252

SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI-TUMOR ACTIVITY

EHA Library, Rogier Mous, 325259

IBRUTINIB, BENDAMUSTINE, RITUXIMAB FOR RELAPSED AND REFRACTORY AGGRESSIVE B CELL LYMPHOMA – FINAL ANALYSIS OF PHASE II CLINICAL TRIAL

EHA Library, Meirav Kedmi, 325262

MOSUNETUZUMAB (MOSUN) MONOTHERAPY FOR ELDERLY/UNFIT PATIENTS (PTS) WITH FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) CONTINUES TO SHOW PROMISING SAFETY AND EFFICACY WITH DURABLE COMPLETE RESPONSES

EHA Library, Adam Olszewski, 325263

DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN PATIENTS OLDER THAN 65 YEARS: ANALYSIS OF 3 YEAR REAL WORLD DATA OF PRACTICE PATTERNS AND OUTCOMES IN ENGLAND

EHA Library, Toby A. Eyre, 325264

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CONDITIONING INCLUDING ALLOGENEIC BISPECIFIC CAR-T CELLS TARGETING BOTH CD19 AND CD22 FOR REFRACTORY/RELAPSED B-CELL NON-HODGKIN LYMPHOMA

EHA Library, Fan Yang, 325265

ECHELON-2, (NCT01777152), 5-YEAR RESULTS OF A RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY OF FRONTLINE BRENTUXIMAB VEDOTIN + CHP VS CHOP IN PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA

EHA Library, Eva Domingo Domènech, 325266

RELAPSE AND SURVIVAL POST-PROGRESSION IN LYMPHOMA PATIENTS AFTER STEM CELL TRANSPLANTATION

EHA Library, Ayumi Fujimoto, 325267

CRS AND ICANS RISK ACROSS THREE CD19 CAR-T CELL PRODUCTS IN PATIENTS WITH AGGRESSIVE NHL

EHA Library, Jordan Gauthier, 325268

COMPARATIVE EFFICACY OF TISAGENLECLEUCEL (TISA-CEL) AND LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

EHA Library, Marie José Kersten, 325270

STUDY OF THE ROLE OF SR PROTEINS IN CYTARABINE TREATMENT RESISTANCE IN ACUTE MYELOID LEUKEMIA

EHA Library, María Luz Morales, 325166

ANALYSIS OF GERMLINE PREDISPOSITION IN PATIENTS WITH MYELOID NEOPLASMS: ASSOCIATION BETWEEN MOLECULAR ALTERATIONS AND CLINICAL HISTORY

EHA Library, Marta Santiago Balsera, 325167

PRECLINICAL DEVELOPMENT OF NOVEL COMBINED CSF1R/FLT3 INHIBITORS IN ACUTE MYELOID LEUKEMIA

EHA Library, Kristine Sletta, 325171

DEEP HYPOXIA REDUCES SENSITIVITY OF ACUTE MYELOID LEUKEMIA CELL LINES TO THE PAN-AURORA INHIBITOR TOZASERTIB

EHA Library, Samantha Bruno, 325173

GENOMIC LANDSCAPE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 70 YEARS

EHA Library, Frank Rücker, 325177

IL-3 RESCUES MUTANT FLT3 AND KIT-POSITIVE AML CELLS FROM TARGETED THERAPY

EHA Library, Elmira Vagapova, 325180

TAGRAXOFUSP IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM: LONG-TERM RESULTS FROM A PIVOTAL TRIAL

EHA Library, Naveen Pemmaraju, 325181

PROGNOSTIC FACTORS OF OVERALL AND RELAPSE-FREE SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION: MULTIVARIATE ANALYSES FROM THE QUAZAR AML-001 TRIAL OF ORAL AZACITIDINE (ORAL-AZA )

EHA Library, Gail Roboz, 325182

TREATMENT FREE REMISSION (TFR) AFTER CEASING VENETOCLAX-BASED THERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Chong Chyn Chua, 325183

SECOND ALLOGENEIC STEM CELL TRANSPLANTATION FOR SECONDARY AML RELAPSING AFTER FIRST TRANSPLANTATION-A COMPARISON BETWEEN MYELOABLATIVE AND REDUCED INTENSITY CONDITIONING: FROM THE ALWP OF THE EBMT

EHA Library, Arnon Nagler, 325185

AGE-SPECIFIC CONDITIONAL RELATIVE SURVIVAL AMONG LONG-TERM ACUTE MYELOID LEUKEMIA (AML) SURVIVORS IN THE NETHERLANDS

EHA Library, Avinash Dinmohamed, 325188

A PHASE 1 STUDY OF GILTERITINIB IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED AML: FINAL RESULTS UPDATE

EHA Library, Keith Pratz, 325191

FOLLOW-UP OF PATIENTS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA IN THE PHASE 3 ADMIRAL TRIAL

EHA Library, Mark Levis, 325192

CYTOPENIA MANAGEMENT IN THE PHASE 3 VIALE-C STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

EHA Library, Andrew Wei, 325193

OUTCOMES IN GILTERITINIB-TREATED FLT3-MUTATED R/R AML PATIENTS WHO UNDERWENT TRANSPLANTATION

EHA Library, Alexander Perl, 325195

RELATIONSHIP BETWEEN VENETOCLAX EXPOSURE AND POST-REMISSION CYTOPENIAS IN SUBJECTS WITH TREATMENT-NAÏVE ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX PLUS AZACITIDINE IN THE VIALE-A STUDY

EHA Library, Deanna Brackman, 325198

COMPARATIVE EFFICACY OF ORAL VERSUS INJECTABLE AZACITIDINE IN PATIENTS WITH AML IN FIRST REMISSION AFTER INTENSIVE CHEMOTHERAPY: AN INDIRECT TREATMENT COMPARISON (SUB-ANALYSIS UPDATE)

EHA Library, Clara Chen, 325200

ALLOGENIC STEM CELL TRANSPLANTATION ABROGATES NEGATIVE IMPACT ON OUTCOME OF AML PATIENTS WITH KMT2A PARTIAL TANDEM DUPLICATION

EHA Library, Gabriel Antherieu, 325211

RESULTS FROM DIAMOND-01 (CLI24-001) TRIAL: FIRST IN HUMAN STUDY OF SEL24/MEN1703, A DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Scott Solomon, 325215

A PHASE 3 STUDY OF ENASIDENIB (ENA) VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH LATE-STAGE MUTANT-IDH2 (MIDH2) RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)

EHA Library, Courtney DiNardo, 325217

INDUCED SYSTEMIC T-CELL SPECIFIC RESPONSES TO MULTIPLE TUMOR-ASSOCIATED ANTIGENS AFTER ALLOGENIC LEUKEMIA-DERIVED DENDRITIC CELL VACCINE DCP-001 IN AML PATIENTS WITH PERSISTENT MRD

EHA Library, Hester J.T. Van Zeeburg, 325218

THE COMBINATION OF AXL INHIBITOR BEMCENTINIB AND LOW-DOSE CYTARABINE IS WELL TOLERATED AND EFFICACIOUS IN ELDERLY RELAPSED AML PATIENTS: UPDATE FROM THE ONGOING BGBC003 PHASE II TRIAL (NCT02488408)

EHA Library, Sonja Loges, 325223

UPDATED PHARMACODYNAMIC AND SURVIVAL OUTCOMES FROM THE AG221-AML-005 TRIAL OF ENASIDENIB (ENA) PLUS AZACITIDINE (AZA) IN PATIENTS WITH MUTANT IDH2 NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (ND-AML)

EHA Library, Courtney DiNardo, 325225

FLT3 INHIBITOR BASED INDUCTION AND ALLOGENEIC STEM CELL TRANSPLANT IN CR1 IMPROVE OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED AML VERY LOW FLT3 ALLELIC BURDEN

EHA Library, Musa Yilmaz, 325228

RE-STRATIFYING THE PROGNOSES OF ACUTE MYELOID LEUKEMIA PATIENTS WITH CEBPA DOUBLE MUTATIONS BY CSF3R MUTATIONS AND MINIMAL RESIDUAL DISEASE

EHA Library, SuJun Gao, 325229

SUPERIOR OUTCOMES FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IN FIRST REMISSION FOR NPM1/FLT3-ITD MUTATED AML

EHA Library, Callum Wright, 325230

PROGNOSTIC SIGNIFICANCE OF ACHIEVING A COMPLETE REMISSION AFTER ONE OR TWO CYCLES OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: ANALYSIS OF DATA FROM THE DATOOL-AML DATABASE

EHA Library, Lukas Semerad, 325233

SORAFENIB IN COMBINATION WITH INTENSIVE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA: A SINGLE-INSTITUTION EXPERIENCE

EHA Library, Irene Urbino, 325234

RISK FACTORS AND MANAGEMENT OF CATHETER-RELATED THROMBOSIS IN ADULT PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Netanel A. Horowitz, 325235

INVESTIGATING THE INCIDENCE OF SECONDARY PRIMARY CANCER IN ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS

EHA Library, Yu-Guang Chen, 325236

ABERRANT CD7 EXPRESSION IN PEDIATRIC ACUTE MYELOID LEUKEMIA: SIGNIFICANCE AND CLINICAL IMPLICATIONS

EHA Library, Fabiana Cacace, 325238

ENASIDENIB IN PATIENTS WITH IDH2-MUTATED ACUTE MYELOID LEUKEMIA (AML). A 'REAL LIFE' MULTI-CENTER EXPERIENCE FROM SPANISH HOSPITALS

EHA Library, Marina Diaz-Beya, 325239

CLI120-001 PHASE1B STUDY OF SEL120/RVU120 IN PATIENTS WITH AML OR HIGH RISK MDS: PRELIMINARY CLINICAL AND PK RESULTS FROM INITIAL DOSE ESCALATION COHORTS

EHA Library, Noemi Angelosanto, 325240

A HOME CARE PROGRAMME FOR THE RAMP-UP AND FIRST COURSES OF TREATMENT WITH VENETOCLAX AND HYPOMETHYLATING AGENTS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA

EHA Library, Alexandra Martínez-Roca, 325241

THE PROGNOSTIC SIGNIFICANCE OF FLT3 INTERNAL TANDEM DUPLICATIONS’ CHARACTERISTICS AND CO-MUTATIONS IN ACUTE MYELOID LEUKEMIA 

EHA Library, Lei-Ming Cao, 325244

SURVIVAL OUCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUCOCYTOSIS

EHA Library, Jonathan Sillar, 325245

GLASDEGIB IN COMBINATION WITH LOW DOSE CYTARABINE FOR ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS FAILING HYPOMETHYLATING AGENTS

EHA Library, Andrius Žučenka, 325246

GEMTUZUMAB OZOGAMICIN ADDED TO HIDAC CONSOLIDATION THERAPY FOR STANDARD-RISK ACUTE MYELOID LEUKEMIA IS SAFE AND EFFICACIOUS

EHA Library, Nurit Horesh, 325247

MULTICENTER OBSERVATIONAL RETROSPECTIVE STUDY ON BACTERIAL/FUNGAL/VIRAL INFECTIONS IN PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA TREATED WITH CPX-351 IN 'REAL-LIFE'

EHA Library, Luana Fianchi, 325251

AN UPDATE ANALYSIS OF PROGNOSTIC SIGNIFICANCE OF PERIPHERAL BLOOD BLASTS ON DAY 7 OF INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, SuJun Gao, 325253

IMPACT OF TREATMENT INTENSITY, MRD AND HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY R/R AML PATIENTS: A MONOCENTRIC RETROSPECTIVE STUDY

EHA Library, Zofia Gross, 325254

PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Olalekan O. Oluwole, MBBS, MPH, 325255

FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY TO ASSESS SAFETY OF TAFASITAMAB OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R‑CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL

EHA Library, David Belada, 325256

EARLY RESPONSE AT ONE MONTH IS PREDICTIVE OF THE OUTCOME OF THE PATIENTS WITH RELAPSE/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CAR T-CELL

EHA Library, Jean Galtier, 325257

CD19 CAR-T IN LESS FIT PATIENTS WITH R/R HIGH-GRADE LYMPHOMA

EHA Library, Andrea Kuhnl, 325258

PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED MCL, WM AND OTHER NHLS: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

EHA Library, Nirav N Shah, 325260

GLOFITAMAB STEP-UP DOSING (SUD): UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL) PATIENTS (PTS)

EHA Library, Carmelo Carlo-Stella, 325261

EFFICACY AND SAFETY OF MOGAMULIZUMAB BY PATIENT BLOOD CLASSIFICATION

EHA Library, Julia Scarisbrick, 325269